News & Media

Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting

Harpoon Therapeutics to Host KOL Event in Person and via Webcast

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September

Disc Medicine to Participate in Upcoming Investor Conferences

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August

Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team

Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma

Portfolio company Disc Medicine raises $157.8 million in public offering

Disc Medicine Announces Closing of Public Offering of Common Stock

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with EPP at EHA 2023 Congress

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Disc Medicine to Participate in the Jefferies Healthcare Conference

Aura Biosciences to Participate in Upcoming Investor Conferences

Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

Portfolio company Ensoma announces closing of Series B Extension

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune

Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases

Financial Results for the Year Ended 31 December 2022, Publication of Annual Report and Notice of Annual General Meeting

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023

Harpoon Therapeutics Presents Data for New ProTriTAC™ Development Candidates in TROP2- and ITGB6-expressing Solid Tumors at AACR 2023

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer

Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Harpoon Therapeutics Announces Closing of $25 Million Private Placement

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023

Imara Announces Stockholder Approval of Merger With Enliven

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan...

Portfolio company Disc Medicine announces $62.5 million financing

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

Aura Biosciences to Participate in Upcoming Investor Conferences

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis

Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform

Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines

Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics

Disc Medicine Announces Completion of Merger with Gemini Therapeutics

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Aura Biosciences Announces Proposed Public Offering of Common Stock

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition

Aura Biosciences to Participate in Upcoming Investor Conferences

Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics

Enliven Therapeutics and Imara Announce Merger Agreement

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Arix Portfolio Company Artios Initiates Phase 2 Study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)

Gemini Therapeutics and Disc Medicine Announce Merger Agreement

Arix Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics

Changes to Board of Directors

Arix Bioscience Announces Interim Results for the Six Months Ended 30 June 2022

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

Harpoon Therapeutics Expands Leadership Team

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia

Artios Appoints Samantha Truex to Board of Directors

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Disc Medicine Presents Positive Results from Phase 1 Clinical Study of DISC-0974 in Healthy Volunteers at the 2022 EHA Annual Congress

STipe Therapeutics appoints Dr Richard Sainson as Chief Scientific Officer to Lead Research and Discovery

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences to Participate in Upcoming Investor Conferences

Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Harpoon Therapeutics Announces Leadership Change

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation

Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)

Imara Reports Full Year 2021 Financial Results and Business Highlights

Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference

Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel

Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals

Depixus raises €30.6M (£26.1 million) in Series A Financing

Arix Portfolio Company Depixus Raises USD 35.4M in Series A Financing

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Disc Medicine Announces Oral Presentation on Bitopertin at the 63rd American Society of Hematology Annual Meeting

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

Aura Biosciences Announces Pricing of Initial Public Offering

Harpoon Therapeutics Announces Change to Management Team and Board of Directors

Business Update and Cancellation of Share Buyback

Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting

Board Changes

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Aura Biosciences Expands Executive Leadership Team and Board of Directors

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

Imara to Participate in Upcoming Investor Conferences

Imara to Present at Upcoming Investor Conferences

Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences

Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases

Arix participates in $90 million Series B financing for Disc Medicine

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

Imara Announces Pricing of Public Offering

Imara Announces Launch of Proposed Public Offering

Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board

Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors

Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting

Imara Reports First Quarter 2021 Financial Results and Business Highlights

Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

Amplyx Pharmaceuticals acquired by Pfizer

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

Artios announces collaboration with Novartis to create next generation DDR cancer therapies

Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders

Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer

Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia

Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

Arix founds new portfolio company Twelve Bio

Annual Results for the Twelve Months ended 31 December 2020

Imara Reports Full Year 2020 Financial Results and Business Highlights

Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease

Aura Biosciences appoints David Johnson to its Board of Directors

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

Completion of sale of VelosBio

Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection (“Flesh-Eating Disease”)

Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs

Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020

Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

Artios and Merck KGaA announce global strategic collaboration

Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

Imara Reports Third Quarter 2020 Financial Results and Business Highlights

VelosBio to be acquired by Merck for $2.75 billion

Harpoon Therapeutics : Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

Quench Bio is named one of Fierce Biotech’s “Fierce 15” Biotech Companies of 2020

Aura Biosciences Announces Dosing of First Patient in Phase 2 Study

Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

Imara to Webcast Conference Call of Second Quarter 2020 Financial Results

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

VelosBio Appoints Dr. Enoch Kariuki as Chief Financial Officer

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

Harpoon Therapeutics Announces Changes to Board of Directors

Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

Imara Receives Orphan Drug Designation for Lead Product Candidate IMR-687 for Sickle Cell Disease

Harpoon Therapeutics updates information for its participation in two upcoming virtual conferences

Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

Harpoon Therapeutics to participate in two upcoming virtual conferences

Arix to present at Proactive One2One Biotech Forum

Arix announces strategic and operational update

Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

Harpoon Therapeutics to Present Interim Clinical Data For TriTAC® HPN424 At The ASCO20 Virtual Scientific Program

Imara to Present Data On IMR-687 In Sickle Cell Disease at The 25th Annual European Hematology Association (EHA) Congress

Amplyx closes $53 million Series C extension

Amplyx advances development of novel antifungal, fosmanogepix

STipe Therapeutics appoints Dr Sonia Quaratino to chair the Scientific and Clinical Advisory Board

Notice of Annual General Meeting

Imara Reports First Quarter 2020 Financial Results and Business Highlights

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Harpoon Therapeutics Doses First Patient With HPN217, a BCMA Targeting TriTAC, For Multiple Myeloma

Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.

STipe Therapeutics appoints Dr Natalie Sacks as Independent Board Member and Dr Richard Bethell as Chief Development Officer

Investment team changes

Harpoon Therapeutics Appoints Two New Members To Its Board Of Directors

Imara prices Nasdaq IPO

Harpoon reports fourth quarter 2019 financial results and provides corporate update

Arix names Dr Roberto Iacone as Entrepreneur in Residence

Update on Imara proposed initial public offering in the United States

Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference

Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

Aura presents updated Phase 1b/2 clinical data for AU-011

Artios Pharma Strengthens Clinical Development Team with Senior Appointments

Imara Appoints Joelle Lufkin, M.P.H., As Senior Vice President Of Development

Arix co-founds Quench Bio with Series A financing

Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration

Harpoon reports third quarter results and provides a corporate update

Artios expands DNA damage response pipeline with new asset

Arix 2019 Capital Markets Day

Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics

Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States

Amplyx unveils expanded pipeline and reports Phase 2 data from lead programme

Imara announces confidential submission of draft registration statement for proposed US IPO

Interim results for the six months ended 30 June 2019

Harpoon reports second quarter 2019 financial results and provides corporate update

Aura Biosciences to Present Long-Term Clinical Data for AU-011 at the 37th Annual Scientific Meeting of the American Society of Retina Specialists

Imara presents initial Phase 2a data for IMR-687

Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress

Harpoon Reports first Quarter 2019 financial results and provides corporate update

Depixus awarded a £600k grant from Innovate UK, the UK’s innovation agency

Harpoon initiates HPN536 Phase 1/2a clinical trial

Imara Appoints Chief Financial & Chief Operating Officer

Aura completes $40 million Series D financing

Artios appoints Dr. Ian Smith as Chief Medical Officer

Annual Results for the year ended 31 December 2018

Arix Bioscience plc Board changes

Imara Appoints Chief Medical Officer

Arix co-leads $63 million Series B investment round for Imara

Harpoon reports full year 2018 financial results and provides corporate update

Upcoming conferences Artios Pharma are attending in 2019

Management and Board changes

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

Harpoon closes initial public offering

Harpoon prices Nasdaq IPO

Update on Harpoon proposed IPO in the United States

Harpoon announces preliminary safety and pharmacology data from its HPN424 Phase 1 trial in prostate cancer

Harpoon announces proposed public offering in the United States

Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011

Depixus awarded a €2.05m grant through the EU’s H2020 SME Instrument Phase 2 programme

Arix Bioscience Co-leads $58 million Series A investment round for VelosBio

Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of Reltecimod In Necrotizing Soft Tissue Infections

Arix Bioscience Plc announces Board changes

Changes announced to executive team to accelerate growth and strategy

Artios completes £65m Series B investment round

Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases

Lord John Hutton steps down from Board of Directors of Arix Bioscience plc

Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)

Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001

Artios exercises option to in-license potential first-in-class nuclease development programme

Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

CEO Letter to Shareholders

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Arix Bioscience leads $30 million financing for Atox Bio

Sir John Banham retires from Board of Directors of Arix Bioscience plc

Arix Bioscience to present at two investor conferences in November

Arix Bioscience appoints Giles Kerr to Board of Directors

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

Arix Bioscience appoints Meghan FitzGerald to Board of Directors

Arix Bioscience hosts Capital Markets Meeting today

Arix Bioscience to Host Capital Markets Meeting in London, 18 September 2017

Arix Bioscience plc announces participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City on 10-12 September 2017

Arix Bioscience plc notes the appointment of Dr Graeme Smith as CSO of Artios Pharma

Artios Pharma appoints Dr Graeme Smith as Chief Scientific Officer

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

Artios signs research collaboration with Masaryk University to develop novel cancer treatments targeting DNA nucleases in the DDR

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

Arix Bioscience CEO interview with Proactive Investors

Maiden Annual Results 2016

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

Arix Bioscience plc signs strategic agreement with Takeda

Artios Strengthens Management Team with the Appointment of Dr Simon Boulton as Vice President Science Strategy

Arix supports Artios Pharma, a new biotech company focused on DNA damage response

Arix Bioscience supports Depixus, an early-stage company focused on nucleic acid sequencing & epigenetic analysis